
BioNTech, BMS Partner to Develop Bispecific Cancer Antibody BNT327
BioNTech and Bristol Myers Squibb Forge $11.1 Billion Global Partnership to Advance Bispecific Cancer Antibody BNT327 Across Multiple Solid Tumor Types In a move that signals a major step forward in the fight against some of the most challenging forms…